602 related articles for article (PubMed ID: 31389318)
1. Effects of Highly Active Antiretroviral Therapy on Albuminuria in HIVinfected Persons.
Adedeji TA; Adebisi SA; Adedeji NO
Infect Disord Drug Targets; 2020; 20(3):374-384. PubMed ID: 31389318
[TBL] [Abstract][Full Text] [Related]
2. Effects of Highly Active Antiretroviral Therapy on Renal Function and Renal Phosphate Handling in African Adults with Advanced HIV and CKD.
Adedeji TA; Adebisi SA; Adedeji NO; Biliaminu SA; Olanrewaju TO
Infect Disord Drug Targets; 2019; 19(1):88-100. PubMed ID: 30027856
[TBL] [Abstract][Full Text] [Related]
3. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015.
Chetty T; Thorne C; Coutsoudis A
PLoS One; 2018; 13(2):e0192805. PubMed ID: 29470508
[TBL] [Abstract][Full Text] [Related]
4. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/lamivudine and efavirenz in antiretroviral-naive patients: virologic, immunologic, and morphologic changes--a 96-week analysis.
Pozniak AL; Gallant JE; DeJesus E; Arribas JR; Gazzard B; Campo RE; Chen SS; McColl D; Enejosa J; Toole JJ; Cheng AK
J Acquir Immune Defic Syndr; 2006 Dec; 43(5):535-40. PubMed ID: 17057609
[TBL] [Abstract][Full Text] [Related]
5. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
[TBL] [Abstract][Full Text] [Related]
6. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz compared with zidovudine/lamivudine and efavirenz in treatment-naive patients: 144-week analysis.
Arribas JR; Pozniak AL; Gallant JE; Dejesus E; Gazzard B; Campo RE; Chen SS; McColl D; Holmes CB; Enejosa J; Toole JJ; Cheng AK
J Acquir Immune Defic Syndr; 2008 Jan; 47(1):74-8. PubMed ID: 17971715
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic drug monitoring study on the switch from coformulated 600-mg efavirenz, tenofovir disoproxil fumarate, and emtricitabine to coformulated 400-mg efavirenz, tenofovir disoproxil fumarate, and lamivudine among HIV-positive patients with viral suppression.
Huang WC; Huang CK; Huang SH; Lin SW; Ou ST; Chen YT; Chen YW; Chang SY; Liu WC; Sun HY; Hung CC
J Microbiol Immunol Infect; 2021 Oct; 54(5):944-951. PubMed ID: 32675042
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings.
Campbell TB; Smeaton LM; Kumarasamy N; Flanigan T; Klingman KL; Firnhaber C; Grinsztejn B; Hosseinipour MC; Kumwenda J; Lalloo U; Riviere C; Sanchez J; Melo M; Supparatpinyo K; Tripathy S; Martinez AI; Nair A; Walawander A; Moran L; Chen Y; Snowden W; Rooney JF; Uy J; Schooley RT; De Gruttola V; Hakim JG;
PLoS Med; 2012; 9(8):e1001290. PubMed ID: 22936892
[TBL] [Abstract][Full Text] [Related]
9. Emulating a target trial of antiretroviral therapy regimens started before conception and risk of adverse birth outcomes.
Caniglia EC; Zash R; Jacobson DL; Diseko M; Mayondi G; Lockman S; Chen JY; Mmalane M; Makhema J; Hernán MA; Shapiro RL
AIDS; 2018 Jan; 32(1):113-120. PubMed ID: 29112066
[TBL] [Abstract][Full Text] [Related]
10. Insulin-Like Growth Factor Is Associated with Changes in Body Composition with Antiretroviral Therapy Initiation.
Erlandson KM; Fiorillo SP; Cardoso SW; Riviere C; Sanchez J; Hakim J; Kumarasamy N; Badal-Faesen S; Lalloo U; Kumwenda J; Campbell TB; Brown TT
AIDS Res Hum Retroviruses; 2017 Sep; 33(9):929-934. PubMed ID: 28403619
[TBL] [Abstract][Full Text] [Related]
11. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
Martínez E; Ribera E; Clotet B; Estrada V; Sanz J; Berenguer J; Rubio R; Pulido F; Larrousse M; Curran A; Negredo E; Arterburn S; Ferrer P; Álvarez ML
HIV Med; 2015 Jul; 16(6):370-4. PubMed ID: 25496141
[TBL] [Abstract][Full Text] [Related]
12. Induction with abacavir/lamivudine/zidovudine plus efavirenz for 48 weeks followed by 48-week maintenance with abacavir/lamivudine/zidovudine alone in antiretroviral-naive HIV-1-infected patients.
Markowitz M; Hill-Zabala C; Lang J; DeJesus E; Liao Q; Lanier ER; Davis EA; Shaefer M;
J Acquir Immune Defic Syndr; 2005 Jul; 39(3):257-64. PubMed ID: 15980684
[TBL] [Abstract][Full Text] [Related]
13. The emergence of drug resistant HIV variants at virological failure of HAART combinations containing efavirenz, tenofovir and lamivudine or emtricitabine within the UK Collaborative HIV Cohort.
Bulteel N; Bansi-Matharu L; Churchill D; Dunn D; Bibby D; Hill T; Sabin C; Nelson M; ;
J Infect; 2014 Jan; 68(1):77-84. PubMed ID: 24055802
[TBL] [Abstract][Full Text] [Related]
14. 96-Week results of abacavir/lamivudine versus tenofovir/emtricitabine, plus efavirenz, in antiretroviral-naive, HIV-1-infected adults: ASSERT study.
Moyle GJ; Stellbrink HJ; Compston J; Orkin C; Arribas JR; Domingo P; Granier C; Pearce H; Sedani S; Gartland M;
Antivir Ther; 2013; 18(7):905-13. PubMed ID: 23899468
[TBL] [Abstract][Full Text] [Related]
15. Comparative outcomes of tenofovir-based and zidovudine-based antiretroviral therapy regimens in Lusaka, Zambia.
Chi BH; Mwango A; Giganti MJ; Sikazwe I; Moyo C; Schuttner L; Mulenga LB; Bolton-Moore C; Chintu NT; Sheneberger R; Stringer EM; Stringer JS
J Acquir Immune Defic Syndr; 2011 Dec; 58(5):475-81. PubMed ID: 21857354
[TBL] [Abstract][Full Text] [Related]
16. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202.
McComsey GA; Kitch D; Daar ES; Tierney C; Jahed NC; Tebas P; Myers L; Melbourne K; Ha B; Sax PE
J Infect Dis; 2011 Jun; 203(12):1791-801. PubMed ID: 21606537
[TBL] [Abstract][Full Text] [Related]
17. Comparative Safety of Antiretroviral Treatment Regimens in Pregnancy.
Zash R; Jacobson DL; Diseko M; Mayondi G; Mmalane M; Essex M; Petlo C; Lockman S; Makhema J; Shapiro RL
JAMA Pediatr; 2017 Oct; 171(10):e172222. PubMed ID: 28783807
[TBL] [Abstract][Full Text] [Related]
18. A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy.
Tang MW; Kanki PJ; Shafer RW
Clin Infect Dis; 2012 Mar; 54(6):862-75. PubMed ID: 22357809
[TBL] [Abstract][Full Text] [Related]
19. Maternal 12-month response to antiretroviral therapy following prevention of mother-to-child transmission of HIV type 1, Ivory Coast, 2003-2006.
Coffie PA; Ekouevi DK; Chaix ML; Tonwe-Gold B; Clarisse AB; Becquet R; Viho I; N'dri-Yoman T; Leroy V; Abrams EJ; Rouzioux C; Dabis F
Clin Infect Dis; 2008 Feb; 46(4):611-21. PubMed ID: 18197758
[TBL] [Abstract][Full Text] [Related]
20. Early upper digestive tract side effects of zidovudine with tenofovir plus emtricitabine in West African adults with high CD4 counts.
Ouattara E; Danel C; Moh R; Gabillard D; Peytavin G; Konan R; Carrou JL; Bohoussou F; Eholie SP; Anglaret X
J Int AIDS Soc; 2013 Apr; 16(1):18059. PubMed ID: 23639243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
